Difference between revisions of "Pamidronate (Aredia)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m (Text replacement - "http://hemonc.org" to "https://hemonc.org") |
||
| (11 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/aredia.pdf Pamidronate (Aredia) package insert]</ref><ref>[ | + | Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/aredia.pdf Pamidronate (Aredia) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/pamidronate.pdf Pamidronate (Aredia) package insert (locally hosted backup)]</ref><ref>[http://www.pamidronate.com Pamidronate manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | ==Disease-specific information== | ||
| + | ===[[Breast cancer]]=== | ||
| + | *Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ, Kennedy I, Allan SG, Mellars K; Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996 Dec 12;335(24):1785-91. [https://doi.org/10.1056/NEJM199612123352401 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8965890/ PubMed] | ||
| + | |||
| + | ===[[Multiple myeloma]]=== | ||
| + | *Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD; Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996 Feb 22;334(8):488-93. [https://doi.org/10.1056/NEJM199602223340802 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8559201/ PubMed] | ||
| + | |||
| + | ===[[Prostate cancer]]=== | ||
| + | *Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 Sep 27;345(13):948-55. [https://doi.org/10.1056/NEJMoa010845 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11575286/ PubMed] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 10: | Line 19: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 10 | + | * 1991-10-31: Initial FDA approval |
==Also known as== | ==Also known as== | ||
| Line 19: | Line 28: | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Bisphosphonates]] | [[Category:Bisphosphonates]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1991]] |
Revision as of 19:32, 23 June 2024
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Disease-specific information
Breast cancer
- Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ, Kennedy I, Allan SG, Mellars K; Protocol 19 Aredia Breast Cancer Study Group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996 Dec 12;335(24):1785-91. link to original article PubMed
Multiple myeloma
- Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD; Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996 Feb 22;334(8):488-93. link to original article PubMed
Prostate cancer
- Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 Sep 27;345(13):948-55. link to original article PubMed
Patient drug information
History of changes in FDA indication
- 1991-10-31: Initial FDA approval
Also known as
- Generic name: pamidronate disodium omega
- Brand name: Aredia, Padium, Pamisol